Antidiabetic and Antihyperlipidemic Activities of the Leaf Latex Extract of Aloe megalacantha Baker (Aloaceae) in Streptozotocin-Induced Diabetic Model

Table 5

Effect of Aloe megalacantha on serum lipid profiles.

Groups	STC (mg/dl)	STG (mg/dl)	HDL-c (mg/dl)	VLDL-c (mg/dl)	LDL-c (mg/dl)
NC	89.00 ± 0.966	95.83 ± 5.87	35.83 ± 1.08	19.17 ± 1.17	34.00 ± 1.67a
DC	189.33 ± 1.54	176.50 ± 2.75	24.17 ± 1.25	35.30 ± 0.55	129.86 ± 2.65
GL5	92.00 ± 2.08	99.67 ± 3.03	37.33 ± 0.49	19.93 ± 0.60	34.74 ± 2.05
AM100	171.33 ± 4.82	151.67 ± 5.32	29.83 ± 1.40	30.33 ± 1.06	111.33 ± 5.49
AM200	165.67 ± 5.24	147.67 ± 4.69	31.83 ± 1.22	29.53 ± 0.94	104.30 ± 5.08
AM400	160.83 ± 5.07	142.17 ± 6.83	34.17 ± 0.79	28.43 ± 1.37	98.17 ± 4.81

Results are expressed in mean ± S.E.M, n = 6; NC = normal control; DC = diabetic control; GL5 = glibenclamide 5mg/kg; AM100 = A. megalacantha extract 100 mg/kg; AM200 = A. megalacantha extract 200mg/kg; AM400 = A. megalacantha extract 400mg/kg; STC = serum total cholesterol; STG = serum triglyceride; HDL-c = high-density lipoprotein cholesterol; VLDL-c = very low-density lipoprotein cholesterol; LDL-c = low-density lipoprotein cholesterol; compared with normal control group, compared with diabetic control; ¹p < 0.05, ²p < 0.01, ³p < 0.001.